CpG motifs: the active ingredient in bacterial extracts?
Top Cited Papers
- 1 July 2003
- journal article
- review article
- Published by Springer Nature in Nature Medicine
- Vol. 9 (7) , 831-835
- https://doi.org/10.1038/nm0703-831
Abstract
The use of bacteria and bacterial extracts for immunotherapy has a checkered past. Recent developments in immunology reveal that these nonspecific immune activators actually work by triggering specific receptors that are expressed by subsets of immune cells. Identification of these receptors and the molecular signaling pathways that they activate has enabled a new era of specific targeted immunotherapy using chemically synthesized mimics of pathogen molecules.This publication has 69 references indexed in Scilit:
- Combined dendritic cell- and CpG oligonucleotide-based immune therapy cures large murine tumors that resist chemotherapyEuropean Journal of Immunology, 2002
- Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartmentsEuropean Journal of Immunology, 2002
- Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848Nature Immunology, 2002
- A role for Toll in autoimmunityNature Immunology, 2002
- CpG Motifs in Bacterial DNA and Their Immune EffectsAnnual Review of Immunology, 2002
- Innate Immune RecognitionAnnual Review of Immunology, 2002
- Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12European Journal of Immunology, 2001
- Identification of CpG oligonucleotide sequences with high induction of IFN-α/β in plasmacytoid dendritic cellsEuropean Journal of Immunology, 2001
- Adjuvant Activities of Immune Response Modifier R-848: Comparison with CpG ODNCellular Immunology, 2000
- CpG‐containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: A new class of vaccine adjuvantsEuropean Journal of Immunology, 1997